PubMed Health⌕ Search

Biomedical subjects

J J Huart

Publications and source records attributed to J J Huart.

At least 55 records · Page 3Linked to original sources
PubMed1987

[Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].

In order to assess the role of specific anti-CMV immunoglobulins in the prevention of severe cytomegalovirus infection in bone marrow transplant recipients, 46 consecutive patients were treated from day 1 to day 90 with injection of hyperimmune immunoglobulin with titres greater than 10,000 (ELISA) prepared from plasma selected for its high antibody titre (greater than 1,250). None of the patients developed CMV interstitial pneumonia; 5 patients developed diffuse pneumonitis, 2 of the aspergillus type and 3 apparently idiopathic, which progressed to fibrosis. There were no deaths directly attributable to CMV infection. This study confirms the efficacy of high dose immunoglobulin therapy in the high risk period for the prevention of sever CMV infection. In the absence of effective antiviral therapy, it is important to use all measures of prevention in patients with bone marrow transplants. The double identification of seronegative and hyperimmune blood donors allows preparation of uncontaminated cell fractions (with respect to CMV) and the selection of hyperimmune plasmas for the preparation of specific immunoglobulins.

Adolescent↗
PubMed1987

[Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].

Cytomegalovirus (CMV) infection is the most frequent cause of lethal infection after bone marrow transplantation. Viremia occurs in 50% of patients seropositive for CMV before transplantation. Interstitial pneumonitis due to CMV occurs in 10% to 20% of patients with 85% mortality. It is known that CMV infection is due to host reactivation of latent CMV infection or to the transmission of the virus by the marrow donor or by blood transfusions. Treatment of CMV infection has been disappointing in the past. All attempts to treat CMV pneumonia with available agents have failed. Recent studies have indicated the usefulness of prophylactic measures and the early treatment of CMV infections. The use of hyperimmune gammaglobulins has given contradictory results. The selection of seronegative marrow donors or blood donors is useful only if the recipient is seronegative. New antiviral drugs have been used recently in preliminary clinical trials. In preliminary studies a guanosine analogue similar to Acyclovir (DHPG Synthex or BWB 759 U Wellcome) has given reasonable hope of disease cure if it is used early before the occurrence of pneumonia. Phosphonoformate (Foscarnet) has also been shown to be active against CMV infection. Both drugs have good antiviral and clinical action in immunosuppressed patients but the results have been disappointing in cases of pneumonia. Relapse occurs frequently after cessation of the treatment and attempts are being made to use maintenance therapy.

Acyclovir↗
PubMed1987

[Immunology and pregnancy].

Immunology in pregnancy is a meeting ground between basic research in biology and daily medical practice. For gynecologists and obstetricians, the authors have attempted to synthesize the acquired knowledge and the current hypotheses on this very complex topic. Three main chapters will be successively approached: a reminder of the normal immune system and its development in the fetus, immunity in pregnant women and the dysimmune pathology during pregnancy, the feto-maternal immune relationship and its possible complications.

Antibody Formation↗
PubMed1987

[Acute lymphoblastic leukemia, Burkitt-cell type, after Hodgkin's disease. Study of 2 cases].

Two cases of Burkitt cell leukaemia (ALL3) occurring 60 and 51 months respectively after treatment of Hodgkin's disease (HD) are described. Clinical, cytological, immunological and cytogenetic features in these patients were comparable with those of the 6 previously published cases and with de novo ALL3. The prognosis of these secondary ALL3 is uniformly poor: our 2 patients died 2 and 14 days after the start of combination chemotherapy, and all the other cases survived less than 60 days after diagnosis. The significance of ALL3 occurring after HD is discussed: the association is probably not fortuitous, and its pathogenic mechanisms probably differ from those intervening in secondary myeloid leukaemias.

Adult↗
PubMed1987

[Ineffective erythropoiesis of immunologic origin with free bilirubin jaundice in an elderly subject].

We report on a 74-year-old male patient who presented with jaundice, highly increased unconjugated bilirubin and slight nonregenerative anemia. Ferrokinetic studies demonstrated ineffective erythropoiesis and red cell survival, studied by 51 Cr, showed moderately increased hemolysis. Other findings showed no evidence of an underlying myelodysplastic syndrome but strongly favored the autoimmune origin of the disorder, with immunologic destruction of erythroblasts (and to a far lesser extent erythrocytes) by autoantibodies.

Aged↗
PubMed1984

[Essential thrombocythemia. Clinical, biological study and developmental study of 61 cases].

The 61 observations of primary thrombocythemia described in this report represent approximately 15% of the cases of polycythemia vera recorded by the authors over the same 18-year period. The group includes 35 females and 26 males, with a mean age of 62. The disease is usually discovered on routine blood tests (half of cases), and more rarely because of hemorrhagic or thrombotic manifestations. Splenomegaly is found in one-third of cases. Platelet count is permanently above 800 X 10(9)/l (mean : 1 500 X 10(9)/l); mild hyperleukocytosis (mean : 16 X 10(9)/l) with predominant neutrophil polynuclears is usual but myelemia is not constant (28% of cases) and always very moderate; red cell parameters are normal in three-fourths of cases, while the remaining patients have anemia, either due to iron depletion or not. Reticulinic myelofibrosis, usually minimal, is found in 40% of cases. Medullary karyotype is always normal, without chromosome Ph1. Platelet functional abnormalities are not constant and do not correlate with the magnitude of thrombocythemia. 51 patients (84%) received myelosuppressive therapy, mainly by busulfan or radioactive phosphorus. Most deaths were due to intercurrent causes and only one patient developed acute leukemia. 71% of patients are alive at five years and subsequent decrease in the actuarial survival curve is very gradual.

Busulfan↗
PubMed1984

[Immunological study of a population of hemophiliacs treated with non-commercial fractions].

We studied lymphocyte subpopulations, serum beta 2 microglobulin, and viral markers in 115 hemophiliacs who are followed and treated at our center. The only clinical or biological anomaly observed is hypergammaglobulinemia. This frequent finding is independent of hemophilia type and of the intensity of substitutive treatment. This group is characterized by the fact that the patients are treated only by locally prepared coagulation fractions, essentially cryoprecipitates for hemophiliacs A, and not containing any derivative of commercial origin. This series is compared to other recent reports, some of which present a high incidence of immunologic anomalies.

Acquired Immunodeficiency Syndrome↗
PubMed1983

[Acute lymphoblastic leukemia with major eosinophilia. Inaugural cardiac insufficiency, endocarditis grafting and valve replacement].

Acute lymphoblastic leukemia (cytologically typical) was diagnosed in an 18-year-old man presenting with major eosinophilia. Prednisone therapy was initiated but sudden congestive heart failure occurred (left ventricular insufficiency with pulmonary edema). Concomitantly, blood counts became normal. Remission of the leukemic process was obtained while severe mitral regurgitation developed, due to bacterial endocarditis. Successful mitral valvuloplasty was achieved. Remission is still persisting one year after diagnosis.

Adolescent↗
PubMed1983

[Burkitt's acute lymphoblastic leukemia. Incidence and cytogenetic aspects].

We report 4 cases of patients, 5, 16, 31 and 55 years old respectively, with Burkitt type ALL. Three of them presented with a hypoaesthesia of the chin tip. The cytological features of abnormal cells were those of L3 subgroup in the FAB classification; they expressed surface immunoglobulin markers. EBV serology was positive in two cases but the titres did not indicate a recent infection. The translocation t(8;14) (q24;q32) was found in all 4 patients. In one case, it was possible to characterize a clone with a 7 neochromosome (7p+) and a clone with a supernumerary 7 isochromosome i(7q)+; in other respects these two clones showed the translocation t(8;14) and only the latter remained in the terminal phase. In these 4 patients the disease progressed dramatically even when haematological remission was obtained (two cases), predominantly due to early neuro-meningeal involvement.

Adolescent↗
PubMed1983

[Treatment of hemorrhagic incidents in acute leukemia and bone marrow aplasia. Personal results 1974-1981].

Transfusional therapy regimens have been investigated in a series of 385 patients treated for acute leukemia (AL). During remission induction, fatal hemorrhages occurred in 0.7% of the patients whereas, during the same time, deaths due to infections were four times more frequent. Platelet concentrates (PC) were usually given on the basis of clinical indications. When the risk of hemorrhage was especially high, as during the induction phase of acute promyelocytic leukemia, prophylactic platelet transfusions seemed to be necessary. Alloimmunization developed in 17% to 52% of the patients depending on their cytologic type and in these cases, PC prepared from single donors had to be used. Among the 57 patients with aplastic anemia (AA), bone marrow transplantation was indicated in 17, and 5 of the 10 grafted patients died from hemorrhages. In AA, as the risk of sensitization to platelet alloantigens was higher, PC prepared from single donors were systematically preferred to standard PC. If bone marrow transplantation was planned, PC from histocompatible donors were ordered.

Acute Disease↗
PubMed1982

["Lymphoid" blastic transformation in chronic myelogenous leukemia. Report of three cases (author's transl)].

Three cases of chronic myelogenous leukemia (CML) were studied, occurring in 22, 43, and 30-year-old-men. Two observations (nos. 1 and 3) concerned typical CML, treated by discontinuous busulfan; in the last patient (no. 2), also presenting in addition with a constitutional deficiency from Hageman factor, diagnosis (Ph 1 chromosome) was based on a moderate leukocytosis with myelemia, spontaneously regressive for more than one year. Chronic phase duration was 17, 16 and 8 months respectively. During the first blast crisis, abnormal cells were rather of granular type in one case (no 1), undifferentiated in the other two. In the three observations, complete remission was easily obtained with prednisolone - vincristine but revealed very brief; 2, 2 and 4 months. Among the three patients a second blast crisis was preceded, in two cases (nos. 1 et 3), by a new CML phase during 3 and 1 months respectively. Treatment was then purely palliative by 6-mercaptopurine and hydroxyurea.

Adult↗